Analysis of factors affecting the prognosis of transcatheter arterial chemoembolization for hepatitis B-related hepatocellular carcinoma

BackgroundPostoperative recurrence is a significant obstacle in hepatocellular carcinoma (HCC) treatment. This study aimed to construct a blood index-based model to predict hepatitis B virus-associated HCC (HBV-HCC) recurrence after curative hepatectomy.MethodsA total of 370 patients who received initially curative hepatectomy for HBV-HCC were included in this study. A novel blood index signature (BIS) was identified and systematically analyzed for its recurrence predictive value. Following this, multivariate Cox regression analysis was performed to build a blood index-based nomogram.ResultsA BIS based on the aminotransferase-to-platelet ratio index and a systemic inflammatory response index was used to construct a nomogram. The model showed good clinical applicability and reliability. Notably, the patients in the high recurrence risk group tended to benefit from adjuvant transcatheter arterial chemoembolization (TACE).ConclusionA reliable model was constructed to predict the HBV-HCC recurrence after curative hepatectomy. This model can guide the surgeons in selecting patients with high recurrence risk patients who may benefit from adjuvant TACE.

Download Full-text

Lamivudine therapy after transcatheter arterial chemoembolization for patients with Hepatocellular carcinoma complicated by hepatitis B virus: an analysis of 30 cases

World Chinese Journal of Digestology ◽

10.11569/wcjd.v16.i15.1700 ◽

2008 ◽

Vol 16 (15) ◽

pp. 1700 ◽

Cited By ~ 1

Author(s):

Yan Li ◽

Zhi-Chao Kan ◽

Tao Han

Keyword(s):

Hepatocellular Carcinoma ◽

Hepatitis B Virus ◽

Hepatitis B ◽

Transcatheter Arterial Chemoembolization ◽

Lamivudine Therapy ◽

B Virus ◽

Arterial Chemoembolization

Download Full-text

Hepatitis B Virus Reactivation Potential Risk Factors in Hepatocellular Carcinoma via Transcatheter Arterial Chemoembolization: A Retrospective Research

Canadian Journal of Gastroenterology and Hepatology ◽

10.1155/2021/8864655 ◽

2021 ◽

Vol 2021 ◽

pp. 1-6

Author(s):

Xiaoguang Wang ◽

Xiaodan Yang ◽

Fei Chen ◽

Shaohan Wu ◽

Zhengwei Song ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Survival Rate ◽

Hepatitis B Virus ◽

Hepatitis B ◽

Transcatheter Arterial Chemoembolization ◽

Hbv Dna ◽

Hbv Reactivation ◽

Virus Reactivation ◽

B Virus ◽

Arterial Chemoembolization

Background. To explore the clinical characteristics of reactivation of hepatitis B virus (HBV) in hepatocellular carcinoma (HCC) after transcatheter arterial chemoembolization (TACE). The pathological correlation of prognosis and hepatitis B virus reactivation has been given detailed analyses in our research. Methods. A total of 108 related TACE-treated HCC clinical data from January 2008 to January 2016 was gleaned and involved in this retrospective analysis. To lucubrate the nuance of survival rates between HBV reactivated group and HBV nonreactivated group, clinical data of each patient was analyzed in detail and refined the retrospective studies. Results. HBV reactivation occurred in 42 patients with a proportion of 38.9%. The detected HBV DNA level ≥104 in patients showed a reactivation rate of 65.8% (25/38), which was significantly higher than the HBV DNA < 104 cases (24.3%, 17/70). Research data revealed a conspicuous lower cellular immunity ( P < 0.01 ) and better 2-year survival rate ( P = 0.03 ) in the HBV-reactivated group when compared to the nonreactivated group. Conclusion. Some of the patients with primary hepatocellular carcinoma possibly had HBV reactivation at post-TACE-therapy. And the predominant risk factors of HBV reactivation are positive HBV test and immunosuppression. Our study suggested that HBV reactivation at post-TACE-therapy is an independent predictor of poor prognosis and low survival rate as well as a crucial reason for poor prognosis and lower survival rate, which indirectly proved that it is urgent to necessitate the antiviral therapy and immune enhancer in improving the curative effect and prognosis of HCC patients.

Download Full-text